Disclosed are a fructose absorption inhibitor that has a monoterpene as the active ingredient, and a preventative or therapeutic agent that is for symptoms or maladies caused by overconsumption of fructose; more specifically, disclosed are a preventative or therapeutic agent for hyperlipidemia, a triglyceride increase suppression agent, and a fructose absorption inhibitor containing a monoterpene.